Leverage HTS, HTA and predictive models to advance lipid nanoparticle formulation development

Introduction: Lipid nanoparticle (LNP) has transformed therapeutic delivery of emerging nucleic acid modalities (1). LNP shows complexity in both formulation compositions and physicochemical attributes (2). To improve formulation development efficiency at the early stage, it would be of significance to employ high-throughput screening (HTS) with automation to optimize LNPs across a large design space, as well as high-throughput analytical (HTA) and advanced modeling approaches to not only control formulation quality attributes, but also provide formulation design insights.